- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 82956-11-4] Nafamostatmesylate
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-B0190A |
| Brand: | MCE |
| CAS: | 82956-11-4 |
Overview
| MDL | MFCD00941430 |
|---|---|
| Molecular Weight | 539.58 |
| Molecular Formula | C21H25N5O8S2 |
| SMILES | CS(=O)(O)=O.O=C(OC1=CC=C2C=C(C(N)=N)C=CC2=C1)C3=CC=C(NC(N)=N)C=C3.CS(=O)(O)=O |
8 Publications Citing Use of MCE
Summary
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05090280 | Ensysce Biosciences|Quotient Sciences|National Institute on Drug Abuse (NIDA) |
Pharmacokinetics
|
December 1, 2021 | Phase 1 |
| NCT04473053 | University of Edinburgh|University of Oxford|Latus Therapeutics |
COVID-19
|
July 3, 2020 | Phase 1|Phase 2 |
| NCT04483960 | University of Melbourne|The Peter Doherty Institute for Infection and Immunity|Australasian Society for Infectious Diseases|Middlemore Clinical Trials|The George Institute|Hunter Medical Research Institute|The University of Queensland |
SARS-CoV-2 Infection (COVID-19)
|
July 28, 2020 | Phase 3 |
| NCT04390594 | Institut Pasteur de Dakar|Fann Hospital, Senegal|Ministry of Health, Senegal|Diamniadio Children Hospital, Senegal|Dalal Jamm Hospital, Senegal|Institut Pasteur Korea |
COVID-19
|
August 13, 2020 | Phase 3 |
| NCT01001403 | Seoul National University Hospital |
Liver Transplantation|Postreperfusion Syndrome
|
March 2009 | Phase 4 |
| NCT05555641 | Wuhan Union Hospital, China |
Critical Illness|Anticoagulation
|
October 1, 2022 | Phase 2 |
| NCT04623021 | Chong Kun Dang Pharmaceutical |
COVID-19
|
September 25, 2020 | Phase 2 |
| NCT04352400 | University Hospital Padova|Yokohama City University|University of Zurich |
COVID19
|
June 4, 2021 | Phase 2|Phase 3 |
| NCT01486485 | Seoul National University Hospital|SK Chemicals Co., Ltd. |
Acute Kidney Injury
|
March 2012 | Phase 3 |
| NCT04418128 | Gyeongsang National University Hospital |
Corona Virus Infection|COVID-19
|
June 10, 2020 | Phase 2|Phase 3 |
| NCT02478242 | Kyungpook National University Hospital |
Acute Kidney Injury
|
July 2010 | Phase 4 |
| NCT01761994 | Yonsei University|SK Chemicals Co., Ltd. |
Acute Kidney Injury
|
September 2007 | Phase 4 |
| NCT04628143 | Chong Kun Dang Pharmaceutical |
COVID-19
|
December 21, 2020 | Phase 2 |
| NCT04406415 | Ensysce Biosciences|National Institute on Drug Abuse (NIDA) |
Pharmacokinetics
|
September 21, 2020 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 50 mg/mL ( 92.66 mM ; Need ultrasonic)
H 2 O : 33.33 mg/mL ( 61.77 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.8533 mL | 9.2665 mL | 18.5329 mL |
| 5 mM | 0.3707 mL | 1.8533 mL | 3.7066 mL |
| 10 mM | 0.1853 mL | 0.9266 mL | 1.8533 mL |
References
- [1] Ikehara S, et al. Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice. Immunology. 1985 Aug;55(4):595-600.
- [2] Homma S, et al. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells. Int Immunopharmacol. 2018 Jan;54:39-45.
- [3] Pak K, et al. Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis. Hinyokika Kiyo. 1988 Jun;34(6):1077-81.
- [4] Markus Hoffmann, et al. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrob Agents Chemother. 2020 Jun; 64(6): e00754-20.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.